Publications by authors named "Nhi Luong"
Introduction: NUT carcinoma (NC) is an underdiagnosed and aggressive poorly differentiated or squamous cell cancer. A subset of NC is sensitive to chemotherapy, but the optimal regimen is unknown. Experts have recommended platinum- and ifosfamide-based therapy based on case reports.
View Article and Find Full Text PDFArticle Synopsis
- NUT carcinoma is an aggressive cancer driven by the BRD4-NUT fusion oncoprotein, but treatments using BET bromodomain inhibitors (BETi) alone have limited effectiveness.
- The study shows that inhibiting EZH2, a protein that silences tumor suppressor genes, with a drug called tazemetostat, effectively blocks the growth of NUT carcinoma cells.
- Combining EZH2 and BET inhibitors leads to stronger anti-cancer effects, blocking tumor growth and prolonging survival in models, highlighting a new strategy for treating NUT carcinoma based on targeting epigenetic regulation.
Article Synopsis
- - NUT carcinoma (NC) is a fast-growing cancer driven by the BRD4-NUT fusion protein, which promotes growth by activating genes; while BET bromodomain inhibitors are a potential treatment, they work better when combined with other therapies.
- - EZH2, a gene silencing enzyme, is essential for NC growth, and its inhibition using tazemetostat significantly reduces NC cell proliferation and restores tumor suppressor gene expression without affecting certain oncogenes.
- - Combining EZH2 inhibitors with BET inhibitors enhances the effectiveness of treatment, leading to greater tumor suppression and longer survival in animal models, with some mice even showing complete remission.
NUT carcinoma (NC) is an extremely aggressive tumor and current treatment regimens offer patients a median survival of six months only. This article reports on the first in vitro studies using immunovirotherapy as a promising therapy option for NC and its feasible combination with BET inhibitors (iBET). Using NC cell lines harboring the BRD4-NUT fusion protein, the cytotoxicity of oncolytic virus (T-VEC) and the iBET compounds BI894999 and GSK525762 were assessed in vitro in monotherapeutic and combinatorial approaches.
View Article and Find Full Text PDFArticle Synopsis
- NUT carcinoma (NC) is a rare and aggressive cancer linked to the BRD4-NUTM1 fusion, which currently has no effective treatment options.
- Researchers identified histone deacetylase (HDAC) inhibitors, specifically panobinostat and a new compound IRBM6, as potential treatments that inhibit NUT's transcriptional activity, repress cancer cell growth, and induce differentiation.
- The study indicates that these HDAC inhibitors alter gene expression related to cancer growth and differentiation and show promise in preclinical models for improving treatment outcomes in NC patients.